A. Nair

A. Nair is a freelance writer based in Mumbai, India.

The Asian nation is strategizing to take the lead over its regional competitors in pharmaceutical exports.

In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.

India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

Multinational firms and governments around the world are flocking to India for R&D partnerships.

Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.